APG777, a High-Affinity Humanized IgG1 Monoclonal Antibody Targeting IL-13, Demonstrates Prolonged Half-Life in Non-Human Primates

Main Article Content

Eric Zhu
Paragon Therapeutics, Inc.

Jason Oh
Paragon Therapeutics, Inc.

Carl Dambkowski
Apogee Therapeutics, Inc.

Hussam Shaheen
Paragon Therapeutics, Inc.

Keywords

atopic dermatitis, eczema, IL-13, type 2 inflammation

References

1. Bieber T. Allergy 2020;75:54–62.

2. Hershey GK. J Allergy Clin Immunol 2003;111:677–90.

3. Gandhi NA, et al. Expert Rev Clin Immunol 2017;13:425–37.

4. Dall'Acqua, et al. J Biol Chem 2006;281:23514–24.

5. Zhu E, et al. EADV 2023 (poster #P0437).

Article Sidebar

PDF
Published
Jan 16, 2024
DOI https://doi.org/10.25251/skin.8.supp.315

Article Details

How to Cite
Zhu, E., Oh, J., Dambkowski, C., & Shaheen, H. (2024). APG777, a High-Affinity Humanized IgG1 Monoclonal Antibody Targeting IL-13, Demonstrates Prolonged Half-Life in Non-Human Primates. SKIN The Journal of Cutaneous Medicine, 8(1), s315. https://doi.org/10.25251/skin.8.supp.315
Issue
Vol. 8 No. 1 (2024): January 2024 Issue
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.